12/15/03



Dkt. No. 03818/1200029-US2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dieter Soll

Serial No.:

10/661,399

Filed:

September 12, 2003

For:

GLUTRNAGLN AMIDOTRANSFERASE - A NOVEL ESSENTIAL

TRANSLATIONAL COMPONENT

December 11, 2003

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- 1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed: (Check one of the boxes A-D)
- [X]A. Within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
- [] B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
- [] C. after (A) and (B) above, but before the mailing date of a final rejection, a notice of allowance, or any other action that closes prosecution, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.

(check one of the boxes "i" and "ii" below:)

- [] i. Counsel states that, upon information and belief, each item of information listed herein was either (a) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- [] ii. A check for the fee set forth in 1. 17(p), presently believed to be \$180, is enclosed.
- [] D. after (A), (B) and (C) above, but before payment of the issue fee: Counsel states that, upon information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS; or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
  - [] i. A check for the fee set forth in 1.17 (p), presently believed to be \$180, is enclosed.
- 2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO-SB/08) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A and/or B and fill in blanks, if appropriate.)

- A. Document(s) \_\_\_\_\_\_ is (are) deemed substantially cumulative to document(s) \_\_\_\_\_\_, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
- [X] B. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120:

09/355,622, filed September 23, 1999.

Applicant Identifies these documents by attaching hereto copies of the forms PTO-892 and PTO-SB/08 from the files of the prior application(s) or a fresh PTO- SB/08 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application.

[] 3. Document Nos. \_\_\_\_\_ are not in the English language. In accordance with 1.98(c), Applicant states:

An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or
application is enclosed.
[] A concise explanation of the relevance of document(s) is found
in the attached search report (see MPEP § 609 A(3)x).
[] A concise explanation of the relevance of document(s) is set
forth as follows: [Insert concise explanation of relevance]
[] A concise explanation of the relevance of document(s) can be found on pages of the specification.
[] A concise explanation of document(s) can be found on the attached sheet.
[] 4. No explanation of relevance is necessary for documents in the English language (see
MPEP § 609 A(3)).
[] 5. Other information being provided for the examiner's consideration follows:
6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be
construed as a representation that a search has been made or that information cited is, or is
considered to be, material to patentability as defined in §1.56 (b), or that any cited document
listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication
indicated for an item is taken from the face of the item and Applicant reserves the right to prove
that the date of publication is in fact different.
CROSS REFERENCE UNDER 37 C.F.R. §1.78 TO RELATED APPLICATIONS
Pursuant to 37 C.F.R. § 1.78, Applicant notes that the above-identified patent application
may be related to the following U.S. Patent Applications:
(1) U.S. Patent Application Serial No, filed
Early and favorable consideration is earnestly solicited.
Respectfully submitted,
S. Peter Ludwig Registration No. 25,351
10gistiation 110. 25,551

DARBY & DARBY P.C. 805 Third Avenue New York, N.Y. 10022 (212) 527-7700 Attorney for Applicant(s)



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/661,399	
11	NFORMATION	l DI	SCLOSURE	Filing Date	September 12, 2003	
S	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Dieter Soll	
_				Art Unit	N/A	
	(Use as many she	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	03818/1200029-US2	

	U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where			
Initials*	No.1	Number-Kind Code <sup>2</sup> ( if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
	AA**	US-6,136,560-B1	10-24-2000	Black et al.				
	AB**	US-6,150,340-B1	11-21-2000	Black et al.				
	AC**	US-6,171,838-B1	01-09-2001	Black				
	AD**	US-6,200,774-B1	03-13-2001	Black et al.				
	AE**	US-6,207,647-B1	03-27-2001	Black et al.				
	AF**	US-6,248,557-B1	06-19-2001	Black et al.				

FOREIGN PATENT DOCUMENTS									
Examiner	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)		Applicant of Cited Document					
	BA**	EP-0 191 221-A1	08-20-1986			$\vdash$			
	BB**	EP-0 786 519-A2	07-30-1997						
	BC**	EP-0 857 786-A1	08-12-1998						
	BD**	EP-0 863 207-A1	09-09-1998						
	BE**	EP-0 857 785-A1	08-12-1998						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached. attached.

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	-2				
	CA**	A** Curnow, AW et al. tRNA-dependent asparagine formation. Nature. 382(6592):589-590 (199					
	CB**	Curnow, AW et al. Glu-tRNA <sup>Glu</sup> amidotransferase: A novel heterotrimeric enzye required for correct decoding of glutamine codons during translation. Proc. Natl. Acad. Sci. (USA) 94(22), pp. 11819-11826.					
CC** Curnow, AW et al. rRNA-dependent amino acid transformations. Nucleic Acids Syn Series 36 (Symposium on RNA Biology, II, RNA: Tool and Target) 36:2-4 (1997).							
	CD**						
	CE**	Kim, SI et al. EMBL Accession No. U49790. Bacilus subtilis PET112-like protein gene, complete cds. Submitted (Feb. 22, 1996).					
	CF**	Schon, A. et al. Protein biosynthesis in organelles requires misaminoacylation of tRNA.  Nature. 331(6152): 187-190. (1988)					
	CG**	Strauch, MA et al. Characterization of the Glutamyl-tRNA <sup>GIn</sup> -toGlutaminyl-tRNA <sup>GIn</sup> Amidotransferase Reactin of Bacilus subtilis. J. Bacteriol., 170(2):916-920. (1988)	_				
	CH**	Tabata, S. EMBL Accession No. D90907. Synechocystis sp. PCC6803 complete genome. Submitted (June 28, 1996).					
	CI**	Wengender, PA et al. Identification of a PutP Proline Permease Gene Homolog from Stephylococcus aureus by Expression Cloning of the High-Affinity Proline Transport System in					
Examiner Signature							



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/661,399	
l In	NFORMATION	1 DI	SCLOSURE	Filing Date	September 12, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Dieter Soll	
				Art Unit	N/A	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	heet 2 of 2		Attorney Docket Number	03818/1200029-US2		

	Escherichia coli. Appl. Env. Microbiol. 61(1):252-259. (1995).
CJ**	Wilcox, M et al. Transfer RNA As A Cofactor Coupling Amino Acid Synthesis with that of Protein, Proc. Natl. Acad. Sci. (USA). 61:229-236 (1968).
CK**	Wilcox, M. Gamma-glutamul phosphate attached to glutamine-specific tRNA. A precursor of glutaminyl-tRNA in Bacillus subtilis. Eur J. Biochem. 11(3):405-12 (1969).
CL**	Wilcox M. Gamma-phosphoryl ester of glu-tRNA-GLN as an intermediate in Bacillus subtilis glutaminyl-tRNA synthesis. Cold Spring Harb. Symp. Quant. Biol. 34:521-528 (1969)
CM**	Curnow, A. W. et al., "Bacillus subtilis Glu-tRNA <sup>Gln</sup> amidotransferase subunits C (gatC), A (gat A) and B (gatB) genes complete cds." EMBL Accession No. AF008553, 18 November 1997.
CN**	Kos, T. et al., Abstract: "Nucleotide sequence of the Aspergillus niger trpC gene: structural relationship with analogous genes of other organisms," Curr. Genet. 13(2):137-144 (1988).
CO**	Walker, M.S., et al., Abstract: "Deletion Analysis of Domain Independence in the TRP1 Gene Product of Neurospora Crassa", Mol Gen Genet., 223(1):49-57 (1990).
CP**	Zalkin, H., "The Amidotransferases", Advances in Enzymology and Related Areas of Molecular Biology 66, A Meister, Ed., pp. 203-205 and 282-287 1993.
CQ**	Zalkin, H., "Glu-tRNAGIn amidotransferase" Methods in Enzymol. Vol. 13 Glutamate, Glutamine, Glutathione, and Related Compounds, A. Meister, Ed., 113:303-305 (1985).
CR	Kim, Sung-II, et al., "A Nuclear Genetic Lesion Affecting Saccharomyces cerevisiae Mitochondrial Translation Is Complemented by a Homologous Bacillus Gene", Journal of Bacteriology, Sept. 1997, Vol. 179, No. 17, pp. 5625-5627.
CS	Curnow, Alan W., et al., "Glutamyl-tRNA <sup>Gln</sup> amidotransferase in Deinococcus radiodurans may be confined to asparagine biosynthesis", Proc. Natl. Acad. Sci., USA Vol. 95, pp. 12838-12843, October 1998.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filling date under 35 U.S.C. 120.

Examiner	 Date	
Signature	 Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill 16.3 9 5 0 9 5 5 an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on December 11, 2003
Date

Signature Savis

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (4 pages) Form PTO SB/08 (2 pages)

Two (2) documents